Cardiovascular diseases remain among the leading causes of morbidity and mortality worldwide, prompting continuous demand for effective and reliable therapeutic agents. Within this context, beta-blockers have established themselves as a cornerstone treatment, addressing hypertension, arrhythmias, and other cardiovascular conditions. Pharmaceutical manufacturers are therefore investing in...